Kymera Therapeutics saw some selling pressure today and moved down -3.27%
It looks like Kymera Therapeutics isn't currently at a very decisive point in regards to support/resistance levels. Kymera Therapeutics has looked pretty good over the last few months. It has definitely cuaght a bid and had a nice run. Over the last 3 months, shareholders are up 6.69 percent. KYMR may hit some resistance around the 28.15 level, more sellers may enter the market here and push price back down. But it's definitely not guaranteed.
The analysts feel fairly neutral on the prospects for Kymera Therapeutics but a little more positive than negative. The current Analysts Sentiment Score is 22.54. Most companies range between (-200 to 200).
Here's a break down of the latest rating changes. Piper Sandler gave a boost to their price target and moved to $56.00 from $39.00 on 2024-02-27. On 2024-02-23 Stifel Nicolaus increased their price target by 57.14% to $55.00. JPMorgan Chase & Co. provided a price target boost of 38.24% to $47.00 from $34.00 on 2024-02-23. On 2024-02-15 Wolfe Research started covering Kymera Therapeutics with a rating of Peer Perform. Bank of America released a downgrade on 2024-01-03 from Buy to Neutral and decided to decrease their price target by -33.33% down to $30.00. On 2023-12-19 Wells Fargo & Company downgraded Kymera Therapeutics from Overweight to Equal Weight and they set their price target at $26.00. Morgan Stanley announced a lowering of their price target to $24.00 from $37.00 on 2023-11-13. HC Wainwright announced a lowering of their price target to $30.00 from $85.00 on 2023-11-03. Leerink Partnrs reiterated a rating of Market Perform on 2023-10-16. On 2023-08-04 Credit Suisse Group increased their price target by 2.78% to $37.00.
Company | Ratings Score
?
Composite analyst sentiment score
|
Positive Ratings | Negative Ratings | Boost Price Target | Lower Price Target |
---|---|---|---|---|---|
KYMR | 22.54 | 5.73 | -55.84 | 147.21 | -52.01 |
Company | YOY Growth Score (typical -20 to +20) | Revision Directions (-6 to +6) |
---|---|---|
KYMR | 0.00 | 0.00 |
We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.
Company | Short Score (typical 1-15)
?
We take into account several different measures and attributes of short interest to create a composite sentiment score. typical range (0 - 30)
|
Short Interest | Days to Cover | Rate of Change | Shares Short |
---|---|---|---|---|---|
KYMR | 13.66 | %13.2106 | 14.2 | -0.66 | 7320000 |
Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.
Ticker | Social Sentiment(1-10) |
---|---|
KYMR |
Company | Score | 1 Day% | 5 Day | 1 Month | 3 Month | 6 Month | 1 Year | RSI | 3mo S-momo ? | 6mo S-momo | 1yr S-momo | Resistance ? | Support | Demark Sell ? | Demark Buy | Short Interest Score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PRTA | Prothena Corporation plc | 0.89 | 2.87 | -3.77 | -18.36 | -34.00 | -52.56 | -60.02 | 32 | -115.85 | -129.98 | -108.82 | -48644.67 | -536.10 | 0 | 0 | 11.1209 |
VCYT | Veracyte, Inc. | 0.84 | 1.30 | 0.41 | -7.78 | -25.25 | -6.45 | -14.43 | 16 | -6.77 | -4.31 | -2.36 | -13628.83 | -197.98 | 0 | 125 | 4.97884 |
VRNS | Varonis Systems, Inc. | 0.83 | 0.37 | 0.96 | -9.65 | -4.79 | 31.33 | 75.11 | 39 | 235.39 | 146.05 | 187.64 | -2197.91 | 163.30 | 0 | 0 | 5.39701 |
YMAB | Y-mAbs Therapeutics, Inc. | 0.8 | 0.87 | 1.48 | -6.78 | 43.55 | 193.79 | 159.97 | 20 | 121.44 | 67.85 | 57.01 | -4077.37 | -18649.02 | 0 | 0 | 10.5121 |
IDYA | IDEAYA Biosciences, Inc. | 0.74 | -1.30 | -10.55 | -13.71 | -12.64 | 43.19 | 155.01 | 46 | 137.69 | 138.94 | 146.53 | -1787.47 | -28324.26 | 0 | 0 | 11.9529 |
PACB | Pacific Biosciences of Ca | 0.74 | -41.98 | -50.60 | -54.81 | -76.09 | -79.39 | -85.06 | 27 | -93.79 | -62.33 | -71.02 | -58610.72 | 0.00 | 0 | 0 | 14.0556 |
DNLI | Denali Therapeutics Inc. | 0.74 | -3.61 | -10.31 | -18.45 | -6.98 | -15.25 | -35.46 | 44 | -10.54 | -23.64 | -26.73 | -17158.84 | -1907.18 | 0 | 0 | 11.2371 |
TXG | 10x Genomics, Inc. Class | 0.73 | -3.49 | -14.97 | -23.01 | -34.10 | -29.68 | -47.45 | 8 | -13.60 | -12.66 | -11.64 | -20764.54 | -2252.51 | 0 | 125 | 8.00406 |
How to use: use the research links to research the asset. Then simply type in a score for each category between (01, 02, 03, 04, 05). 05 being the most bullish and 01 being the most bearish. It will automatically calculate the average and combine it with the technical score to create an overall score to rank prospects by. You can also type notes into each field.